Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26036266 | 0.85 | KMT2A (0.45) | MAPTKMT2AFFAR1FFAR4ALDH1A1 | |
| SCHEMBL26036263 | 0.83 | KMT2A (0.55) | MAPTKMT2AFFAR1ALDH1A1LMNA | |
| SCHEMBL26036272 | 0.83 | KMT2A (0.55) | MAPTKMT2AFFAR1ALDH1A1LMNA | |
| SCHEMBL12154210 | 0.81 | KMT2A (0.59) | MAPTKMT2AALDH1A1LMNAHTT | |
| SCHEMBL31321642 | 0.80 | AKR1C3 (0.55) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL26036243 | 0.80 | PTGS2 (0.48) | ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL31321634 | 0.80 | KMT2A (0.56) | MAPTKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL26036252 | 0.78 | PTGS2 (0.47) | ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL26036255 | 0.77 | PTGS2 (0.46) | LMNAHSD17B10ALOX5CYP4F2CYP4A11 | |
| SCHEMBL12154251 | 0.76 | KMT2A (0.50) | MAPTKMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | DIC CORPORATION (JP) | 2023-08-29 | — | — | US | disclosed |
| US-20230131540-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT AND COMPOUND | DIC CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | OCIAD2, PKN2, SKP1 | MAPT 1064/4885KMT2A 802/4885MEN1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.